iBio, Inc. Files 8-K Report

TL;DR

iBio filed an 8-K, updating its address and former names. Nothing major, just housekeeping.

AI Summary

On November 4, 2025, iBio, Inc. filed an 8-K report. The filing indicates that the company is located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121, and its telephone number is (979) 446-0027. The company was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.

Why It Matters

This filing provides updated corporate information for iBio, Inc., including its current address and former names, which is important for investors and stakeholders to maintain accurate records.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting corporate information and does not disclose any new material events, financial changes, or strategic shifts.

Key Players & Entities

• iBio, Inc. (company) — Registrant
• 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 (location) — Principal executive offices
• iBioPharma, Inc. (company) — Former name
• InB:Biotechnologies, Inc. (company) — Former name

FAQ

From the Filing

0001420720-25-000035.txt : 20251104 0001420720-25-000035.hdr.sgml : 20251104 20251104160309 ACCESSION NUMBER: 0001420720-25-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251104 ITEM INFORMATION: Other Events FILED AS OF DATE: 20251104 DATE AS OF CHANGE: 20251104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251448850 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20251104x8k.htm 8-K iBio, Inc._November 4, 2025 0001420720 false 0001420720 2025-11-04 2025-11-04 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road , Suite 200 San Diego, California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 8.01       Other Events.   On November 4, 2025, iBio, Inc. (the “Company”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) noting it has regained compliance with Nasdaq Lising Rule 5550(a)(2). As previously reported, on July 29, 2025, the Company received a letter from Nasdaq indicating the Company was not in compliance with the Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock failed to maintain